Albert Font Pous | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Albert Font Pous is active.

Explore More

Publication

Featured researches published by Albert Font Pous.

Journal of Clinical Oncology | 2018

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles; Alejo Rodriguez-Vida; Ignacio Duran; Simon J. Crabb; Michiel S. van der Heijden; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; María José Méndez-Vidal; Cristina Suárez; A. Lorch; Cora N. Sternberg; Mark Linch; Shah-Jalal Sarker; Aaron Prendergast; Kelly Mousa; Daniel Castellano

Journal of Clinical Oncology | 2017

Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIERE—A SOGUG trial.

Albert Font Pous; Sergio Vazquez-Estevez; Aranzazu Gonzalez del Alba; Begoña Mellado; Ovidio Fernandez Calvo; Maria Jose Mendez; María José Juan Fita; Angel Rodriguez Sanchez; Begoña Pérez-Valderrama; Enrique Gallardo; Carmen Santander; M Isabel Sáez; Javier Puente; Teresa Alonso; Maria Piedad Fernandez Perez; Alberto J Martinez; Maria Jose Lopez-Andreo; Enrique Grande; Enrique Gonzalez-Billalabeitia; Daniel Castellano

Journal of Clinical Oncology | 2018

A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.

Daniel Castellano; Miguel Angel Climent; Ignacio Duran; Begoña Mellado; Jesús M. Paramio; Francisco X. Real; Jose Luis Ramirez; Juan Luis Sanz; Albert Font Pous

Journal of Clinical Oncology | 2018

Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT).

Albert Font Pous; Javier Puente; Daniel Castellano; Francisco X. Real; Miguel Angel Climent; Aranzazu Gonzalez del Alba; Stéphane Oudard; Federico Vazquez Mazon; Rafael Morales Barrera; Juan Virizuela Virizuela; Núria Sala; Begoña Pérez-Valderrama; Xavier Garcia del Muro; Pedro L. Fernández; Pedro Jares; Iban Aldecoa; Neil Gibson; Josep Serra; Esteban Rodrigo Imedio; Begoña Mellado

Journal of Clinical Oncology | 2018

NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA).

Liangxuan Zhang; Hartmut Koeppen; Daniel J. Maslyar; Dimitri Fillos; Na Xu; Wai Y. Chan; Albert Font Pous; Viorel Jinga; Christophe Massard; Sergio Bracarda; George Daniel Radavoi; Ugo De Giorgi; Jose Angel Arranz Arija; Ruth Riisnaes; Daniel Nava Rodrigues; Johann S. de Bono; Steven Gendreau

Journal of Clinical Oncology | 2017

Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trial—On behalf of SOGUG.

Enrique Grande; Albert Font Pous; Natalia Fernández Núñez; Aranzazu Gonzalez del Alba; Begoña Mellado; Ovidio Fernandez Calvo; Maria Jose Mendez; Miguel Angel Climent; Ignacio Duran; Enrique Gallardo; Angel Rodriguez Sanchez; Carmen Santander; M Isabel Sáez; Javier Puente; Maria Piedad Fernandez Perez; Vincenza Conteduca; Daniel Wetterskog; Gerhardt Attard; Daniel Castellano; Enrique Gonzalez-Billalabeitia

Journal of Clinical Oncology | 2017

Predictors of radiologic progression free survival (rPFS) during abiraterone acetate (AA) treatment in a randomized phase II study of AA maintenance in combination with docetaxel (D) after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): ABIDO-SOGUG trial.

Daniel Castellano; María José Méndez-Vidal; Javier Puente; M Isabel Sáez; Albert Font Pous; Ignacio Duran; Carmen Santander; Alfredo Sanchez-Hernandez; Jose Angel Arranz Arija; Teresa Alonso; Begoña Mellado; Martin Lázaro Quintela; Aranzazu Gonzalez del Alba; Emilio Esteban; Pablo Maroto; Javier Cassinello; Miguel Angel Climent

Journal of Clinical Oncology | 2017

Phase II clinical and pharmacokinetic (PK) trial of zalypsis (Z) in patients with urothelial carcinoma (UC) progressing after a first-line platinum-based regimen.

Ismael Ghanem; Joan Carles; Joaquim Bellmunt Molins; Cinthya Coronado; José Pablo Maroto; Albert Font Pous; Rafael Morales; Cristina Suárez; Olatz Etxaniz; Laia Capdevila; Cristina Martin Lorente; Cleofe Rodriguez; Carmen Kahatt; Manuel Luque; Daniel Castellano

Journal of Clinical Oncology | 2017

BRCA1, RAP80, and AEG-1 mRNA expression in resectable muscle-invasive bladder cancer (MIBC) patients (p) treated with neoadjuvant cisplatin-based chemotherapy.

Albert Font Pous; Pamela Celiz; Miquel Taron; Iman Chaib; Jose Luis Gago; Pedro Mendez; Jose Javier Sanchez; Olatz Etxaniz; Luis Cechini; Nuria Pardo; Belen Sanchez; Jose Luis Cuadra; Ivana Valverde; Oscar Buisan; Luis Ibarz; Rafael Rosell

Journal of Clinical Oncology | 2017

Phase II trial of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have progressed within less than 12 months after cisplatin-based chemotherapy: A Spanish Oncology Genitourinary Group (SOGUG) study.

Jose Angel Arranz Arija; Miguel Angel Climent Duran; Albert Font Pous; Mirta Garcia Alonso; Enrique Gallardo Diaz; Xavier Garcia del Muro; Aranzazu Gonzalez del Alba; Nuria Lainez Milagro; Martin Lázaro Quintela; Marta López-Brea; M. Pilar Lopez Criado; Raquel Luque Caro; Cristina Martin Lorente; Maria Jose Mendez Vidal; Alvaro Pinto Marin; M.I. Sáez; Carmen Santander Lobera; Sergio Vázquez Estévez; Juan Virizuela Echaburu; Ignacio Duran

Explore More